SCHEMBL6939626

SCHEMBL6939626

CCOc1cc(CBr)ccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.51
CYP4A11 Q02928 1/20 0.51
LMNA P02545 6/20 0.47
ALDH1A1 P00352 4/20 0.47
HTT P42858 3/20 0.47
MAPT P10636 3/20 0.47
XBP1 P17861 2/20 0.47
POLB P06746 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
GALR3 O60755 1/20 0.42
NR2F2 P24468 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
CALM1 P0DP23 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11949151 0.86 CSNK2A1 (0.53) CYP4F2CYP4A11ALDH1A1HTTMAPT
SCHEMBL3721818 0.85 CSNK2A1 (0.51) CYP4F2CYP4A11LMNAALDH1A1MAPT
SCHEMBL16200384 0.85 LMNA (0.56) CYP4F2CYP4A11LMNAALDH1A1HTT
SCHEMBL10117589 0.84 SMN1; SMN2 (0.50) CYP4F2CYP4A11LMNAALDH1A1MAPT
SCHEMBL4743479 0.84 CYP4F2 (0.44) CYP4F2CYP4A11LMNAALDH1A1HTT
SCHEMBL28612540 0.83 LMNA (0.48) LMNAALDH1A1HTTMAPTXBP1
SCHEMBL7651768 0.82 CALM1 (0.49) LMNAALDH1A1HTTMAPTPOLB
SCHEMBL20079748 0.81 LMNA (0.47) LMNAALDH1A1HTTMAPTXBP1
SCHEMBL6939966 0.81 CSNK2A1 (0.56) LMNAALDH1A1HTTMAPTXBP1
SCHEMBL1121617 0.81 LMNA (0.47) CYP4F2CYP4A11LMNAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A CYP4F2 639/4885CYP4A11 218/4885LMNA 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.